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The purpose of this study was to investigate the maximum tolerated
doses, dose-limiting toxicities, efficacy, and pharmacokinetic pro-
files in the combination of irinotecan and paclitaxel. Eligibility
criteria included age 75 years or younger, good performance status,
adequate organ function, and unresectable non–small cell or exten-
sive disease of small cell lung cancer. Irinotecan was administered
on days 1 and 8 over 90 minutes, and paclitaxel was administered on
day 8 over 3 hours after 90 minutes from the end of the irinotecan
infusion. Irinotecan and paclitaxel were dose-escalated from 40 and
135 mg/m2 and repeated every 4 weeks. The authors also adminis-
tered a higher dosage with preventive granulocyte colony-stimulat-
ing factor support from day 9. Thirty-one patients were assessed for
toxicities and responses. Dose-limiting toxicities were neutropenia
and febrile neutropenia. The dose of irinotecan 60 mg/m2 and
paclitaxel 200 mg/m2 with preventive granulocyte colony-stimulat-
ing factor support was tolerable and suitable for a phase II trial. Nine
of 25 (36%) patients with non–small cell and all six patients with
small cell carcinoma achieved partial response. The areas under the
concentration versus time curves of irinotecan and its metabolites on
day 8 were significantly higher than on day 1. This combination
therapy must be planned only after careful consideration of the
drug–drug interaction.
Key Words: Lung cancer, Irinotecan, Paclitaxel, Phase I, Pharma-
cokinetics.
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Chemotherapy for non–small cell lung cancer (NSCLC)has recently improved survival by using platinum com-
pounds and new drugs (e.g., vinorelbine, gemcitabine, tax-
anes, and irinotecan).1 Chemotherapy for extensive disease of
small cell carcinoma (ED-SCLC) has also improved survival
using cisplatin and irinotecan.2 Although these regimens
statistically improved survival, the benefits are far from
satisfactory. There are comparatively few reports of nonplati-
num regimens, and we do not have sufficient knowledge
about these regimens regarding maximum tolerated doses
(MTD), toxicities, responses, and pharmacokinetic profiles.
However, irinotecan and paclitaxel have shown antitumor
activity for both non–small cell and small cell carcinoma as
a single agent.3–6 This combination is also reported to have
additive or supra-additive antitumor effects for lung cancer
cells in vitro by using an isobologram.7,8 Therefore, we
conducted this combination phase I study to evaluate MTD,
dose-limiting toxicities (DLTs), and pharmacokinetics in this
combination therapy. We also evaluated the response rate and
pharmacokinetic profiles.
Before planning this study, we performed this combi-
nation trial by another administration schedule.9 In the prior
trial, irinotecan was administered over 90 minutes on days 1,
8, and 15 and paclitaxel was given by infusion over 3 hours
on day 2. Starting doses of irinotecan and paclitaxel were 50
and 135 mg/m2, respectively. DLTs were neutropenia and
febrile neutropenia, and MTD was the starting dose. Further-
more, most of the patients could not receive irinotecan on
days 8 and 15 because of neutropenia. Although the neutro-
penia from this combination regimen was intolerable, an
antitumor response was seen in the majority of the patients,
suggesting that this combination might provide good antitu-
mor activity and that an alternative administration schedule
was needed to use these drugs. In this new trial, we therefore
modified the administration schedule to escalate dose inten-
sity while avoiding severe toxicities.
PATIENTS AND METHODS
Patient Selection
Patients with unresectable NSCLC or ED-SCLC were
eligible for the trial. Pathologic confirmation and assessable
lesions were necessary before study entry. Previous chemo-
therapy or radiotherapy, if given, must have been completed
at least 4 weeks before entry. Other eligibility criteria in-
cluded age 20 to 75 years, Eastern Cooperative Oncology
Group performance status of 0 to 1, estimated life expectancy
of at least 3 months, and adequate organ function defined as
follows: white blood cell count greater than or equal to 4000
cells/l, absolute neutrophil count greater than or equal to
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2000 cells/l, platelet count greater than or equal to 100,000
cells/l, serum creatinine less than or equal to 1.2 mg/dL,
bilirubin less than or equal to 1.5 mg/dL, serum alanine
aminotransferase (ALT) or aspartate aminotransferase (AST)
less than twice the upper limit of normal, and PaO 2 greater
than or equal to 60 mmHg. Patients with interstitial pneumo-
nia, active infection, unstable cardiac disease, uncontrolled
diabetes mellitus, pleural or cardiac effusion that required
drainage, or symptomatic brain metastasis were ineligible.
Our hospital institutional review committee approved this
study, and all patients provided written informed consent.
Treatment
Irinotecan was administered on days 1 and 8 over 90
minutes, and paclitaxel was administered on day 8 over 3
hours after 90 minutes from the end of irinotecan infusion
(Figure 1). All patients received premedication for paclitaxel
and vomiting. The treatment was repeated every 4 weeks. The
latter therapy was permitted using preventive granulocyte
colony-stimulating factor (G-CSF) support from day 9 if
patients experienced DLT of leukopenia or neutropenia and
achieved partial response or stable disease on the previous
course. The criteria for administration on day 8 were white
blood cell count greater than or equal to 3000 cells/l and
other eligibility criteria before study entry. If patients did not
clear this criteria for day 8, their treatment was cancelled and
they were excluded from the evaluation of toxicities and
responses.
Dose Escalation
The dose escalation schedule is shown in Table 1.
Evaluation of DLTs for dose escalation was performed for the
first course of chemotherapy. DLTs were defined using Na-
tional Cancer Institute Common Toxicity Criteria (version
2.0)10 as grade 4 neutropenia lasting 5 days or more, other
grade 4 hematologic toxicities, neutropenic fever, or grades 3
and 4 toxicities in other organ systems except for nausea and
vomiting. Three patients were assigned to each dose level.
When all three patients did not experience DLT, we shifted to
the next dose level. If one or two patients experienced DLT,
an additional three patients were entered at the dose level
before dose escalation. When at least three patients were
found to have DLT, the dose was defined as the MTD. After
the MTD was determined without preventive G-CSF support,
we continued this study with preventive G-CSF support from
day 9 until the recovery of neutropenia. We permitted the
latter therapy by using preventive G-CSF support if patients
who experienced DLT achieved stability or a partial re-
sponse. Intrapatient dose escalation was not permitted. World
Health Organization tumor evaluation criteria were used for
tumor response evaluation.11,12
Pharmacokinetic Analysis
Blood samples for pharmacokinetic analysis were ob-
tained on days 1 and 8 in the first course. We collected
samples by means of a peripheral venous catheter at the
following times from the end of irinotecan infusion: 0, 15, 30,
90, 180, 240, 300, 420, 540, and 1410 minutes on day 1; and
0, 15, 30, 90, 180, 240, 270, 285, 300, 360, 420, 540, 630, and
1410 minutes on day 8, respectively. To analyze the pharma-
cokinetics of paclitaxel and the influence on the pharmaco-
kinetics of irinotecan by paclitaxel, several processes were
FIGURE 1. Treatment schedule of irinotecan and paclitaxel.
TABLE 1. Dose Escalation Schedule
Dose Level CPT-11 (mg/m2) Paclitaxel (mg/m2)
1 40 135
2 50 135
3 60 135
4 60 150
5 60 175
6 60 200
CPT-11, irinotecan.
TABLE 2. Patient Characteristics
Characteristic Value
No. of patients enrolled 31
Median age (range) (yr) 62 (36–75)
Sex
Male 23
Female 8
PS
0 4
1 27
Prior chemotherapy
Yes 2
No 29
Type of lung cancer 18
Adenocarcinoma 6
Squamous cell carcinoma 1
Large cell carcinoma 6
Small cell carcinoma
Median no. of courses (range) 2 (1–5)
PS, performance status.
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added on day 8. Heparinized tubes were used, and the plasma
was immediately separated by centrifugation and stored at
–20°C until analysis. Plasma concentrations of irinotecan, its
metabolites (SN-38 and SN-38G), and paclitaxel were mea-
sured using high-performance liquid chromatography on the
reported conditions.13,14
The area under the plasma concentration-time curve
(AUC) of irinotecan, its metabolites, and paclitaxel were
calculated by the trapezoidal method with extrapolation to
infinity using WinNonlin (version 1.1; Scientific Consulting,
Inc., Apex, NC).
The AUC of irinotecan, SN38, and SN-38G on day 1
were compared with those on day 8 using paired t test and
Wilcoxon matched-pairs signed ranks test. Clearance of pac-
litaxel was compared with reported data in monotherapy.
RESULTS
Patient Characteristics
Twenty-six men and eight women were enrolled in the
study and were treated between March of 1999 and Novem-
ber of 2002 at Kinki University Hospital in Osaka, Japan.
Two men in level 3 and one man in level 4 were excused
because of the criteria for administration of day 8. One
showed grade 3 elevation of ALT and ileus, another showed
grade 2 elevation of ALT, and the other exhibited grade 2
rash. These patients were excluded from evaluation of toxic-
ities and responses at each dose escalation. Finally, 31 pa-
tients were evaluated for their toxicities and responses, and
blood samples were drawn on both day 1 and day 8 from 31
patients. The characteristics of the 31 patients are listed in
Table 2.
Toxicities and Dose Escalation
Major toxicities are hematologic toxicities, diarrhea,
and elevation of AST and ALT. Other nonhematologic tox-
icities are mild. Details are listed in Table 3. In level 2, one
patient developed grade 3 liver dysfunction and the other
developed neutropenic fever. In level 3, all patients devel-
oped grade 4 neutropenia and two of three patients developed
neutropenic fever. Although level 3 had not reached the
definition of MTD at this point, we judged that the dose of
level 3 was probably MTD, and that further continuation of
level 3 was dangerous. However, two patients who had
neutropenic fever did not develop DLT in the second course
of level 3 with preventive G-CSF support. We decided,
therefore, to continue this study with preventive G-CSF
support from level 3. One patient added to level 3 with
preventive G-CSF support did not develop DLT. Most pa-
tients received second or later courses on schedule in each
level. Although the schedules were delayed in a few patients,
the reasons were not toxicities. This study was subsequently
continued until level 6, and the dose did not reach the MTD
with preventive G-CSF support. Although level 6 with G-
CSF support was tolerable, this phase I study was discontin-
ued because each dose was close to the recommended dose
for monotherapy in Japan. We estimated that the recom-
mended dose for phase II study was irinotecan 60 mg/m2
(days 1 and 8) and paclitaxel 200 mg/m2 (day 8) with
preventive G-CSF support from day 9.
TABLE 3. Major Toxicities
Level 1 Level 2 Level 3 Level 3’ (G-CSF) Level 4 (G-CSF) Level 5 (G-CSF) Level 6 (G-CSF)
No. of patients 3 6 3 2*  1 6 6 6
Neutropenia
G3 1 0 0 1 2 0 1
G4 (5 days) 1 4 3 1 2 2 1
G4 (5 days) 0 0 0 0 0 0 0
Neutropenic fever 0 1 2* 0 1 1 1
AST or ALT
G2 0 0 0 0 0 0 0
G3 0 1 0 0 0 0 0
Diarrhea
G2 0 1 1 0 1 0 1
G3 0 0 0 0 0 1 0
DLT patients 0 2 2* 0 1 2 1
*Two patients who had neutropenic fever in level 3 were treated with preventive G-CSF support in second courses as level 3’. Level 3’ was tolerable for them. G, National Cancer
Institute Common Toxicity Criteria grade; DLT, dose-limiting toxicity.
TABLE 4. Tumor Responses
Level Patients PR SD PD
1 3 3
2 6 2  1* 2 1
3 4 1 1 2
4 6 0  3* 2 1
5 6 4  2*
6 6 2 2 2
*Patients with ED-SCLC. †NSCLC (25 patients): PR, 9 (36%; 95% CI, 18–57%).
ED-SCLC (6 patients): PR, 6 (100%; 95% CI, 61–100%). PR, partial response; SD,
stable disease; PD, progressive disease; CI, confidence interval.
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Tumor Responses
Nine of 25 (36%) patients with NSCLC achieved par-
tial response, and all six patients with ED-SCLC achieved
partial response (Table 4).
Pharmacokinetics
Pharmacokinetic analyses were conducted on 31 patient
blood samples. AUCs of irinotecan and its metabolites on day
8 were significantly higher than on day 1 (Table 5). Clearance
of paclitaxel (day 8) was 14.3  5.3 liters/hr/m2.
DISCUSSION
Several other studies of this combination were report-
ed.15–17 Both paclitaxel and irinotecan were administered
weekly in some studies, and patients were given paclitaxel on
day 1 and irinotecan on days 1, 8, and 15 in some studies.
DLTs and other major toxicities were hematotoxicities and
diarrhea. These toxicities were similar to those in this study.
Administration of irinotecan on day 8 or 15 was generally
skipped in the weekly schedule, or administration of pacli-
taxel on day 1, because of hematotoxicities. This study
schedule was designed to avoid skipping administration on
day 8 and to elevate dose intensity and its efficacy by using
G-CSF without any risky administration on day 15. Other
studies did not increase the dosage with G-CSF and did not
treat patients with ED-SCLC. This combination showed com-
paratively stronger hematologic toxicity than the other plati-
num combination regimens or nonplatinum regimens as in-
dicated from our results and the other reports on this
combination.
Platinum-based combinations with third-generation
drugs are standard regimens in the treatment of advanced
NSCLC.1,18,19 However, a recent meta-analysis has reported
that 1-year survival was not significantly prolonged when
platinum-based therapies were compared with third-genera-
tion–based combination regimens.20 Platinum-free doublet
regimens are expected to offer improved survival without
decreasing quality of life. Although this trial showed a re-
sponse rate similar to other nonplatinum regimens, hemato-
toxicities were stronger than those of the other regimens.
Therefore, this combination therapy might not be suitable for
the treatment of NSCLC.
In the treatment of small cell lung cancer, the regimen
of cisplatin and irinotecan ensures better survival than the
regimen of cisplatin and etopside.2 There have been very few
reports of platinum-free doublet regimens based on third-
generation drugs in small cell lung cancer. The response rate
of this study regimen was noteworthy. Although the number
of patients with small cell carcinoma was limited, all patients
achieved partial response (95% confidence interval,
61–100%). This combination showed similar or better re-
sponse than the combination of cisplatin and etoposide, and
this regimen might be as effective as the combination of
cisplatin and irinotecan. Therefore, this combination is pro-
posed as an attractive regimen for small cell lung cancer
chemotherapy.
In this trial, three persons were withdrawn from treat-
ment by the criteria of day 8 and thus excluded from evalu-
ation. We know from our previous study that this combina-
tion may cause severe neutropenia and that some patients
occasionally show stronger toxicities for irinotecan than
most. For example, it has been suggested that the polymor-
phism of UDP-glucuronosyltransferase might raise severe
toxicities.21,22 If only single administration of low-dose iri-
notecan produced toxicities that conflicted with the criteria of
day 8, we can regard that patient as an anomaly regarding
irinotecan. At this point, our administration schedule seems to
be safe for this combination.
In the pharmacokinetic study, AUCs of irinotecan and
its metabolites on day 8 were significantly higher than those
of day 1. Clearance of paclitaxel was similar to that in many
previously reported studies. We observed a 90-minute inter-
val between irinotecan infusion and paclitaxel infusion to
avoid severe drug interactions. We concluded that the mech-
anism of drug elimination is competitive because we had
found indications of interaction from the pharmacokinetic
investigation in our previous study. Irinotecan and its metab-
olite are mainly excreted by P-glycoprotein and cMORT in
the liver, and paclitaxel or its vehicle (Cremophor EL) will
compete in some stage of excretion. Noninterval administra-
tion of paclitaxel and irinotecan would heighten the AUC and
the risk of toxicities. It has been advised in phase II trials that
the administration time schedule of a phase I study be
retained because it is very likely that the MTDs are different
in each administration schedule. If the interval between
irinotecan and paclitaxel administration is shorter or the order
of administration is reversed, the possible pharmacokinetic
interaction and toxicities might be much stronger. This com-
bination therapy must be planned carefully with due consid-
eration of the drug–drug interaction.
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